Chart-Typ:
Zeitraum:
| Alumis Inc.: Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen |
| Alumis Inc.: Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus | -Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted... ► Artikel lesen |
| Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen |
| Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen |
| Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.